Provident Financial plc set for FTSE 100 exit and NMC Health plc to replace it

Provident Financial plc (LON:PFG) is heading out of the FTSE 100 (INDEXFTSE:UKX) and NMC Health plc (LON:NMC) is in line for promotion from the FTSE 250 (INDEXFTSE:MCX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Troubled subprime lender Provident Financial (LSE: PFG) is set to be relegated from the FTSE 100 when the FTSE committee publishes its latest quarterly index review this evening. Private hospitals group NMC Health (LSE: NMC) is poised for promotion to the top index from the second-tier FTSE 250.

The reshuffle is based on market capitalisations at yesterday’s closing prices and, according to my calculations, Royal Mail is also set to exit the FTSE 100, having slipped just below the automatic demotion level at the eleventh hour. My sums say this would pave the way for housebuilder Berkeley to be promoted in its place.

Unmitigated disaster

Provident Financial has seen £3.2bn wiped off its stock market value since the last FTSE quarterly review in May. Its shares have nosedived 70% from 3,057p to 906.5p at yesterday’s close. Two spectacular profit warnings have done for the group. It’s now valued at £1.3bn and doomed for demotion to the FTSE 250. It’s a sorry day for a company that had gained its FTSE 100 status in December 2015, having thrived after the financial crisis, as traditional banks withdrew from higher-risk lending.

The cause of Provident’s woes has been a switch to a new operating model in its home credit division. This has seen a fundamental change from its traditional model of serving customers via an army of self-employed agents to employing in-house ‘Customer Experience Managers’ and greater use of software. So far, it’s been an unmitigated disaster, with reduced agent effectiveness resulting in a progressive deterioration in collections, sales and customer retention.

Positives and negatives

There’s an argument that the fall in Provident’s shares is overdone, put forward by major shareholder Neil Woodford, among others. Making some huge assumptions, he suggested a valuation of three times potential 2019 earnings with a potential dividend yield for the year of 15% — albeit at the time he was writing (the day of the second profit warning), the shares were trading at an intra-day price of around 520p.

However, with the company having downgraded its home credit division, profit for the current year to £60m from £110m at the first profit warning and then to a loss of between £80m and £120m just nine weeks later, this is a major crisis and there is zero earnings visibility. The chief executive has departed, the dividend has been suspended and one of the products of its banking division is also under investigation by the Financial Conduct Authority. I can only see Provident as a stock to avoid for the time being.

New entrant

There’s a far happier story for NMC Health’s shareholders, with their company’s ascension to the FTSE 100. Since the last quarterly review, its shares have risen 22% from 2,187p to yesterday’s close of 2,670p, giving it a market cap of £5.5bn.

This fast-growing and leading private sector healthcare operator in the United Arab Emirates trades on a high 34 times current-year forecast earnings. However, with earnings expected to grow at 30% a year for the next couple of years, I see scope for the shares to make further advances and for the company to climb up the FTSE 100 rankings. As such, I rate the shares a ‘buy’.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. 

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »